Thrombopoietin Receptor Levels in Tumor Cell Lines and Primary Tumors
Author Information
Author(s): Connie L. Erickson-Miller, Antony Chadderton, Anna Gibbard, Jennifer Kirchner, Kodandaram Pillarisetti, Katherine Baker, Lini Pandite, Iman El-Hariry, Yasser Mostafa Kamel, Yuan Liu, Anne-Marie Martin, Conrad Messam
Primary Institution: GlaxoSmithKline
Hypothesis
The study investigates the expression of thrombopoietin receptor (TPO-R) mRNA in various tumor cell lines and primary tumors.
Conclusion
TPO-R agonists are unlikely to induce proliferation in certain tumor types, but may help correct thrombocytopenia in clinical settings.
Supporting Evidence
- MPL mRNA was expressed at very low levels in most tumor cell lines analyzed.
- None of the renal cell carcinoma tumors expressed detectable MPL mRNA.
- 132 out of 151 RCC tumors showed detectable levels of EPOR mRNA.
- Only 3 out of 355 tumor cell lines demonstrated high MPL mRNA expression.
- Thrombopoietin receptor agonists may preferentially stimulate megakaryocytic cells.
Takeaway
This study looked at how much of a specific receptor is found in different cancer cells, and found that it’s usually very low, which means a new treatment might not work on these cancers.
Methodology
The study used microarray analysis and qRT-PCR to examine MPL mRNA expression in tumor cell lines and patient tumor samples.
Limitations
The study did not measure the expression of TPO-R protein on the cell surface, which may affect the interpretation of the results.
Participant Demographics
The study included tumor samples from patients with renal cell carcinoma, prostate cancer, lymphoma, colon cancer, and sarcomas.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website